Literature DB >> 2004315

Attributes and survival patterns of multiple primary cutaneous malignant melanoma.

B K Gupta1, M R Piedmonte, C P Karakousis.   

Abstract

From a series of 1495 patients with primary cutaneous malignant melanoma (PCMM), 26 patients (1.73%) had multiple primary cutaneous malignant melanoma (MPCMM). This report describes the attributes and survival patterns in this small, but important, subgroup of patients with PCMM. Of 26 patients, 23 had two primaries, two had three primaries, and one had six primaries. Five patients had synchronous and 21 patients had metachronous MPCMM. The median interval between the occurrence of the first and subsequent PCMM in these patients was 1.93 years. The estimated 5-year survival rate from the first melanoma was 83.5%; that from the last melanoma was 53.1%. In summary, MPCMM is a distinct biologic phenomenon. A second or subsequent malignant melanoma should be treated like a primary melanoma.

Entities:  

Mesh:

Year:  1991        PMID: 2004315     DOI: 10.1002/1097-0142(19910401)67:7<1984::aid-cncr2820670727>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Multiple primary melanoma: risk factors and prognostic implications.

Authors:  A D Burden; J P Vestey; J M Sirel; T C Aitchison; J A Hunter; R M MacKie
Journal:  BMJ       Date:  1994-08-06

2.  Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.

Authors:  Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

3.  Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM).

Authors:  Robert Ferguson; Alexi Archambault; Danny Simpson; Leah Morales; Vylyny Chat; Esther Kazlow; Rebecca Lax; Garrett Yoon; Una Moran; Richard Shapiro; Anna Pavlick; David Polsky; Iman Osman; Tomas Kirchhoff
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.